Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ: CPIX · Real-Time Price · USD
4.280
-0.080 (-1.83%)
Apr 2, 2025, 4:00 PM EDT - Market closed

Company Description

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally.

The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis.

Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals logo
Country United States
Founded 1999
IPO Date Aug 11, 2009
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 91
CEO A. Kazimi

Contact Details

Address:
1600 West End Avenue, Suite 1300
Nashville, Tennessee 37203
United States
Phone 615 255 0068
Website cumberlandpharma.com

Stock Details

Ticker Symbol CPIX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001087294
CUSIP Number 230770109
ISIN Number US2307701092
SIC Code 2834

Key Executives

Name Position
A. J. Kazimi MBA Founder, Chairman, President and Chief Executive Officer
John Michael Hamm C.M.A. Vice President and Chief Financial Officer
James Lowrance Herman Vice President of Trade and Distribution and Chief Compliance Officer
ChristopherT. Bitterman Vice President of Sales and Marketing
Jean W. Marstiller Senior Vice President of Administrative Services and Corporate Secretary
Adam S. Mostafa Managing Director of Banking and Investor Relations

Latest SEC Filings

Date Type Title
Mar 19, 2025 8-K Current Report
Mar 18, 2025 ARS Filing
Mar 10, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 10, 2025 DEF 14A Other definitive proxy statements
Mar 7, 2025 10-K Annual Report
Mar 4, 2025 8-K Current Report
Feb 19, 2025 8-K Current Report
Feb 14, 2025 424B5 Filing
Feb 14, 2025 8-K Current Report
Feb 13, 2025 SCHEDULE 13G Filing